Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system - PubMed (original) (raw)
Review
Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system
B Vergès et al. Diabetes Metab. 2011 Dec.
Abstract
Aim: Glucagon-like peptide-1 (GLP-1) belongs to the incretin hormone family: in the presence of elevated blood glucose, it stimulates insulin secretion and inhibits glucagon production. In addition, GLP-1 slows gastric emptying. GLP-1 secretion has also been reported to potentially affect patients with type 2 diabetes (T2DM) compared with non-diabetics and, as enzymatic inactivation by dipeptidyl peptidase-4 (DPP-4) shortens the GLP-1 half-life to a few minutes, GLP-1 receptor agonists such as exenatide twice daily (BID) and liraglutide have been developed, and have become part of the management of patients with T2DM. This review focuses on the potential beneficial effects of these compounds beyond those associated with improvements in blood glucose control and weight loss, including changes in the cardiovascular and central nervous systems.
Methods: This was a state-of-the-art review of the literature to evaluate the relationships between GLP-1, GLP-1 receptor agonists, weight and the cardiovascular system.
Results: GLP-1 receptor agonists improve glucose control and do not significantly increase the risk of hypoglycaemia. Also, this new class of antidiabetic drugs was shown to favour weight loss. Mechanisms may involve central action, direct action by reduction of food intake and probably indirect action through slowing of gastric emptying. The relative importance of each activity remains unclear. Weight loss may improve cardiovascular outcomes in patients with T2DM, although GLP-1 receptor agonists may have other direct and indirect effects on the cardiovascular system. Reductions in myocardial infarct size and improvements in cardiac function have been seen in animal models. Beneficial changes in cardiac function were also demonstrated in patients with myocardial infarcts or heart failure. Indirect effects could involve a reduction in blood pressure and potential effects on oxidation. However, the mechanisms involved in the pleiotropic effects of GLP-1 receptor agonists have yet to be completely elucidated and require further study.
Conclusion: These compounds may play an important role in the treatment of patients with T2DM as their potential effects go beyond glucose-lowering (weight loss, potential improvement of cardiovascular risk factors). However, to better understand their place in the management of T2DM, further experimental and clinical prospective studies are required.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.
Similar articles
- Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS. Jellinger PS. Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245. Postgrad Med. 2011. PMID: 21293084 Review. - Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.
Anagnostis P, Athyros VG, Adamidou F, Panagiotou A, Kita M, Karagiannis A, Mikhailidis DP. Anagnostis P, et al. Diabetes Obes Metab. 2011 Apr;13(4):302-12. doi: 10.1111/j.1463-1326.2010.01345.x. Diabetes Obes Metab. 2011. PMID: 21205117 Review. - Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF, Mannucci E, Ahrén B. Deacon CF, et al. Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24. Diabetes Obes Metab. 2012. PMID: 22471248 Review. - Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease.
Lebovitz HE, Banerji MA. Lebovitz HE, et al. Diabetes Technol Ther. 2012 Jun;14 Suppl 1:S43-50. doi: 10.1089/dia.2012.0022. Diabetes Technol Ther. 2012. PMID: 22650224 - Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ. Neumiller JJ. J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. J Am Pharm Assoc (2003). 2009. PMID: 19801361 Review.
Cited by
- Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study.
Østergaard HB, Humphreys V, Hengeveld EM, Honoré JB, Mach F, Visseren FLJ, Westerink J, Yadav G, Mosenzon O; CAPTURE investigators. Østergaard HB, et al. Diabetes Obes Metab. 2023 Feb;25(2):435-443. doi: 10.1111/dom.14887. Epub 2022 Oct 24. Diabetes Obes Metab. 2023. PMID: 36199242 Free PMC article. - The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease.
Zaky A, Glastras SJ, Wong MYW, Pollock CA, Saad S. Zaky A, et al. Int J Mol Sci. 2021 Sep 6;22(17):9641. doi: 10.3390/ijms22179641. Int J Mol Sci. 2021. PMID: 34502562 Free PMC article. Review. - The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism.
Banerjee Y, Pantea Stoian A, Silva-Nunes J, Sonmez A, Rizvi AA, Janez A, Rizzo M. Banerjee Y, et al. Expert Opin Drug Saf. 2021 Nov;20(11):1309-1315. doi: 10.1080/14740338.2021.1970744. Epub 2021 Aug 25. Expert Opin Drug Saf. 2021. PMID: 34424130 Free PMC article. Review. - Cardio- and Neurometabolic Adipobiology: Consequences and Implications for Therapy.
Frohlich J, Chaldakov GN, Vinciguerra M. Frohlich J, et al. Int J Mol Sci. 2021 Apr 16;22(8):4137. doi: 10.3390/ijms22084137. Int J Mol Sci. 2021. PMID: 33923652 Free PMC article. Review. - DPP4 Activities Are Associated with Osteopenia/Osteoporosis and Fracture Risk in Newly Diagnosed Type 2 Diabetes.
Qiu M, Zhai S, Liu D. Qiu M, et al. Int J Endocrinol. 2020 Nov 27;2020:8874272. doi: 10.1155/2020/8874272. eCollection 2020. Int J Endocrinol. 2020. PMID: 33312197 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous